Sign Out
Primary hypercholesterolaemia: Monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia in whom a statin is considered inappropriate or is not tolerated.
Co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia who are not appropriately controlled with a statin alone.
Homozygous familial hypercholesterolaemia (HoFH): Co-administered with a statin is indicated as adjunctive therapy to diet for use in patients with HoFH.
Homozygous sitosterolaemia (phytosterolaemia): Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolaemia.
